Sector News

Looking to save $1.6B, Sanofi starts with 500-plus job cuts in France

February 2, 2016
Life sciences

Sanofi is starting its latest round of job cuts with more than 500 in its home country. According to media reports, almost 300 open R&D jobs won’t be filled, with another 250-plus cuts hitting Sanofi’s commercial operations and corporate offices.

Some layoffs have been expected since November, when the company said it would slash 1.5 billion euros’ worth of annual costs. Sanofi had estimated a few hundred job cuts in France per year for three years, Le Figaro reports..

Sanofi officials met with union leaders Tuesday to unveil some details. Exact numbers vary, but multiple media reports say the company plans to cut 280 to 296 open R&D positions. More than 100 additional jobs will go in administrative and support functions, union rep Thierry Bodin told Bloomberg, with an additional 155 cut in commercial.

The payroll reductions could affect manufacturing and vaccines as well as R&D, sales, and management functions, some union sources told the French media. Individual union committees will meet Thursday, Le Figaro says.

Sanofi officials assured the unions that production sites would not be closed and most of the affected employees will be offered “fully-funded” retirement packages, the French newspaper reports.

The latest round of cuts follows a series of workforce reductions in Sanofi’s French operations since 2008. The company has shrunk its payroll by about 1,300 jobs in France since 2008, in a combination of thousands of job cuts and hiring in other functions.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.